Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07828249 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma

Study acronym: PRadR2
StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study is an open label, Phase I study investigating the safety and clinical activity of 4 IV injections of 161Tb-PSMA-1 in patients with mccRCC. This trial is divided in 2 parts: * The dose escalation part aims to assess the safety of 161Tb-PSMA-1 in up to 21 patients with mccRCC. Eligible patients will be treated with escalating activity of 161Tb-PSMA. * The extension part aims to collect preliminary clinical activity data of the proposed treatment.
Trial Details
NCT Number NCT07828249
Lead Sponsor Centre Leon Berard
Conditions
(from sponsor)		 Metastatic Clear Cell Renal Cell Carcinoma
Related terms Clear-cell metastatic renal cell carcinoma
Enrollment 26 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov